Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer ; volume:04 ; number:02 ; year:2015 ; pages:095-097
South Asian journal of cancer ; 04, Heft 02 (2015), 095-097
- Beteiligte Personen und Organisationen
-
Ali Shah, Syed Imran
- DOI
-
10.4103/2278-330X.155699
- URN
-
urn:nbn:de:101:1-2021022619364591037730
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ali Shah, Syed Imran
Ähnliche Objekte (12)
Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer
Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Androgen deprivation in prostate cancer: benefits of home-based resistance training
Correction: Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer
Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
PTP1B regulates lymphocytes responses androgen deprivation
Docetaxel in the management of PSA progression following primary androgen deprivation for prostate cancer
Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer
Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Androgen deprivation in prostate cancer: benefits of home-based resistance training
Correction: Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer
Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
PTP1B regulates lymphocytes responses androgen deprivation
Docetaxel in the management of PSA progression following primary androgen deprivation for prostate cancer
Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer
Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Androgen deprivation in prostate cancer: benefits of home-based resistance training
Correction: Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
Discovery of prostate specific antigen pattern to predict castration resistant prostate cancer of androgen deprivation therapy
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer
Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
PTP1B regulates lymphocytes responses androgen deprivation